NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Talquetamab Phase 2

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed & Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

TALMMY1001-Part 3

The corresponding study (NCT03399799) is the Phase 1 part of the study and TALMMY1001- Part 3 is the Phase 2 part of the study.

---

Sponsor

Janssen Research & Development, LLC

---

ClinicalTrials.gov Identifier: NCT04634552

Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

First Posted : November 18, 2020

Click here to see details on ClinicalTrials.gov

---